Patient education ‘useless’ when it comes to Eliquis adherence: study

Carly Helfand

Good news for partners Bristol-Myers Squibb and Pfizer: In a Phase IV of their new-age anticoagulant, , atrial fibrillation patients posted rates near 90%. And the icing on the cake? The company didn't need to shell out on to get them there.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS